Regarding the type of induction therapy used prior to ASCT, MM patients that received a combination of proteasome inhibitors (PIs) plus immunomodulatory drugs (IMIDs) plus steroids presented significantly lower median percentages of (i) total B-cells (2.5% vs. 4.2%, p = 0.009), (ii) total BCP (1.2% vs. 1.9%, p = 0.013), particularly stage II BCP (1% vs. 1.8%, p = 0.008), and (iii) total nPC (0.05% vs. 0.1%, p = 0.001), especially CD19+ nPC (0.04% vs. 0.1%, p = 0.001) at day+100 post-ASCT, compared to those patients who received PIs plus steroids or IMIDs plus steroids and cyclophosphamide. Here, CD19 is linked to Miyoshi myopathy.